Transforming all Tumor Sites: The Power of Systemic Enveloped Virotherapy
SITC 2024
Publications
Transforming Tumor Immune Microenvironments with a Novel Systemic Enveloped Oncolytic Virotherapy Targeting All Tumor Sites
ASCO Annual Meeting 2024
Non-Clinical Evidence Supporting the Upcoming CLD-201 Clinical Trial: Cell-Based Oncolytic Virotherapy for Multiple Solid Tumors
ASCO Annual Meeting 2024
Stem Cell Platforms for Enhanced Oncolytic Virotherapy
Festival of Biologics
Deciphering Anticancer Mechanisms of Oncolytic Virus-loaded Stem Cells
American Association for Cancer Research
Annual Meeting – SITC 2023 – Nov 1st to 5th 2023 in San Diego, CA, USA.
SUPERNOVA1 (SNV1), A NOVEL ONCOLYTIC-CELL BASED PLATFORM FOR CANCER THERAPY
Development of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic Virotherapy
National Center for Biotechnology Information
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial
Lancet Oncology
Abstract 6542: CAL1 vaccinia virus as oncolytic agent and potential use of cell-based platform to enhance its therapeutic effects
American Association for Cancer Research
Abstract 4473: Evaluation of the potential of oncolytic vaccinia virus delivered by autologous SVF to modulate innate and adaptive immunity in patients with diverse solid and hematological malignancies
American Association for Cancer Research
Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms.
Journal of Clinical Oncology
Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients
The Journal of Translational Medicine